Fasken Martineau DuMoulin LLP advised Research Capital Corporation on the matter. GeneTether Therapeutics Inc. (CSE: GTTX), an innovative genetic medicines company, completed an initial public offering of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
